Intuitive Surgical, Inc. ISRG
- Market cap
- $140.7B
- P/E
- 45.8×
Follow ISRG
Intuitive Surgical, Inc. (ISRG) Free cash flow
Intuitive Surgical, Inc.'s free cash flow for fiscal 2025 was $2.5B, up 91.0% from $1.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.3B. Over the past ten years it has ranged from $725.2M (fiscal 2015) to $2.5B (fiscal 2025) — the current reading is the highest in ten years. Intuitive Surgical, Inc. ranks 1st of 55 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $2.5B | 91.03% |
| FY2024 | $1.3B | 73.93% |
| FY2023 | $749.6M | (21.79%) |
| FY2022 | $958.4M | (45.23%) |
| FY2021 | $1.7B | 53.06% |
| FY2020 | $1.1B | (2.50%) |
| FY2019 | $1.2B | 19.39% |
| FY2018 | $982.2M | 3.04% |
| FY2017 | $953.2M | (7.73%) |
| FY2016 | $1.0B | 42.46% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $948.4M | 10.98% |
| Mar 2026 | $854.6M | 17.07% |
| Dec 2025 | $730.0M | (0.76%) |
| Sep 2025 | $735.6M | 31.33% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ISRG Intuitive Surgical, Inc. | $3.3B |
| BDX Becton, Dickinson and Company compare | $3.2B |
| MDLN Medline Inc. compare | $2.3B |
| RMD ResMed Inc. compare | $1.6B |
| ALC Alcon compare | $1.6B |
| BAX Baxter International Inc. compare | $815.0M |
| WST West Pharmaceutical Services, Inc. compare | $436.9M |
| RGEN Repligen Corporation compare | $110.3M |
| SOLV Solventum Corporation compare | −$118.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ISRG
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement